GlassScriptPhysician profile
Louis Pham
NPI 1235897281
$8,204.00
in general payments reported to CMS, 2019-2025
20 companies · $4,325 in 2025
The $4,325 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,879 · 2025: $4,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,194 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,194.35 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,472.98 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $1,304.87 | 2024-2025 | |
| Dermavant Sciences, INC. | $1,086.13 | 2024 | Vtama |
| Abbvie INC. | $1,076.19 | 2024-2025 | |
| Leo Pharma INC. | $766.38 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $358.44 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $328.71 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $312.64 | 2024-2025 | Zoryve |
| Organon LLC | $278.09 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $250.08 | 2024-2025 | |
| Incyte Corporation | $248.11 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $243.22 | 2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $128.64 | 2024-2025 | Tremfya |
| Almirall LLC | $86.22 | 2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $68.94 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $62.51 | 2024-2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $48.77 | 2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $45.53 | 2024 | Dupixent |
| Botanix Sb INC | $21.85 | 2025 | Sofdra |
| Lnhc, INC | $15.70 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.